subject: Experts called for urgent research into post-marketing drugs "economic element" - drugs, listing - the pharmaceutical industries [print this page] Experts called for urgent research into post-marketing drugs "economic element" - drugs, listing - the pharmaceutical industries
Drugs not only in pre-market evaluation must be rigorous, in the practical application listing still require enormous efforts to ensure its safety and effectiveness of the human body. However, post-market evaluation is not just limited to inspection under the conditions of its extensive use of the efficacy and safety of other factors that affect health, including drug selection, the affordability of the patients, and society, also to the nature of vital.
However, there is an important issue today is that many Medicine Expert attention for drug and human clinical results (such as clinical efficacy and quality of life), to the neglect of economic factors. To this end, the experts called for economic evaluation of medicines should be in the drug post-marketing study of a place.
Evaluation of content-rich Pharmacoeconomics is a multi-disciplinary science related to its very wide scope of the study, related to health economics, risk analysis, technology assessment, clinical evaluation, epidemiology, decision sciences and health services research. Pharmacoeconomics Research and optimal allocation of health resources in China is closely related to its evaluation of the pharmaceutical products, services and overall value of planning, emphasis on prevention, treatment and disease management interventions in the clinical, economic and humanistic outcomes.
China Pharmaceutical University International Business School Professor Qiu Jiaxue Medicine, said, has been listed on the economic evaluation of medicines is a new topic. Underdeveloped in China's current socio-economic conditions, the rapid growth of medical costs and more attention. Since the introduction of evidence-based medicine, pharmacoeconomics in our "cost - effect" of attracting more attention, PMS relative "cost - effectiveness" evaluation has become an important factor in guiding drug.
Fudan University School of Public Health Professor Hu Shanlian introduction of new drugs after the listing should be a comparative study of similar products, including the price of drugs, efficacy, Adverse reactions And quality of life of patients in terms of best use for the drugs to provide information to guide and standardize the clinical medication. This requires, in addition to vigorously promote "national essential drug" use, but also the use of new science and technology that have been listed for further evaluation of drugs to a drug on a reasonable application of the minimum costs for maximum benefit.
Listing drugs economics research interests include: active reference drugs on the same comparative study, follow-up study of new products, understanding the adaptability of the supply side, demand side of drug conversions, as well as drug risk assessment, the value of drugs research, business opportunities evaluation. The study has effective risk analysis, drug budget impact analysis, meta-analysis, systems analysis, drug prices will pay for the threshold of the new drug research and development role.
Professor Qiu Jiaxue said Pharmacoeconomic evaluation of integrated enterprise products included in the results Health Insurance List of drugs and for drug reimbursement pricing, production costs provide the basis for compensation, will help research new drug on the market after the pattern of long-term studies also strongly support the market development of new drugs.
Professor Hu Shanlian said, from the foreign experience, the control of drug costs from the price controls simply shift to promote the rational use of medicines based full range of integrated control. Pharmacoeconomic evaluation of drugs can cost more than the control key to providing important information: such as "Drug Reimbursement List" and the formulation of drug prices, "clinical treatment guidelines," the formulation of such.
